The federal caretaker government of Pakistan has stirred another controversy with its recent decision to increase the prices of 146 lifesaving drugs. These medicines, including vaccines and antibiotics, are vital for treating a range of conditions like cancer, heart diseases etc. This move comes amid a backdrop of surging inflation and economic difficulties in the country.
According to health officials, the Drug Regulatory Authority of Pakistan had initially proposed raising prices for 262 drugs. However, the government opted to implement price hikes for only 146 of them, focusing specifically on those classified as lifesaving. Pharmaceutical companies have been granted permission to adjust the prices of these critical medications accordingly. It is worth noting that the government will continue to regulate the prices of 464 drugs listed in the National Essential Medicines List, which are deemed essential for public health and accessibility.
This decision has sparked debates and raised concerns among citizens, particularly those reliant on these medications for their well-being. As patients grapple with the impact of increased costs, the government faces the challenge of maintaining a balance between affordability and availability of crucial drugs.
In a country where access to healthcare remains a pressing issue, decisions regarding drug pricing hold significant implications. The hope is that policymakers will strike a delicate balance—one that ensures both affordability and the availability of lifesaving treatments for all.
